, Volume 6, Issue 6, pp 57–62 | Cite as

DDW-Kongress in San Diego CA — Teil 3

UpToDate bei Kolon, Mikrobiom und CED

  • Birgit TerjungEmail author
  • Manfred Gross

Auf dem amerikanischen Gastroenterologie-Kongress (DDW, Digestive Disease Week), der 2019 in San Diego CA stattfand, erfuhren mehr als 14.000 Teilnehmer alles über aktuelle Standards, Neuigkeiten und wissenschaftliche Erkenntnisse zu Kolon, Mikrobiom und chronisch entzündlichen Darmerkrankungen. In einer Serie von Artikeln werden in GASTRO NEWS die Inhalte der wichtigsten Vorträge und Abstracts präsentiert.


  1. 1.
    Tabung FK et al. J Nutr 2017;147:1567–77CrossRefGoogle Scholar
  2. 2.
    Ma W et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1595Google Scholar
  3. 3.
    Nguyen LH et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1875Google Scholar
  4. 4.
    Taneja SL et al. Gastroenterology 2019;156(6) Suppl 1: OP 838Google Scholar
  5. 5.
    Ciezki KJ et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Mo1627Google Scholar
  6. 6.
    Chang SH et al. Gastroenterology 2019;156(6) Suppl1: Abstract Mo1717Google Scholar
  7. 7.
    Fritscher-Ravens A et al. Gastroenterology 2019;156(6) Suppl1: OP946Google Scholar
  8. 8.
    Heyde S et al. Gastroenterology 2019, 156(6) Suppl1: Abstract Su1625Google Scholar
  9. 9.
    Garcia-Zermeno KR et al. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1658Google Scholar
  10. 10.
    Leite G JH et al. Analysis of the small intestinal microbiome reveals marked differences from stool microbiome in a large scale human cohort: redefining the „gut microbiome.“ Gastroenterology 2019;156(6) Suppl 1: Abstract Sa1911Google Scholar
  11. 11.
    Haydek JP et al. Differences among luminal and mucosal microbiota among fecal microbiota transplant recipients. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1863Google Scholar
  12. 12.
    Villanueva-Millan M et al. Deep sequencing of the entire human small intestine: a comparison to stool microbiome in the REIMAGINE study. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1909Google Scholar
  13. 13.
    Jin G et al. Intestine microbiome aspiration (IMBA) capsule: a new autonomous and minimally-invasive device for whole gut microbiome sampling and mapping. Gastroenterology 2019;156(6) Suppl1: OP977Google Scholar
  14. 14.
    Stallmach A et al. Long-term multidonor fecal microbiota transfer (FMT) by oral capsules for active ulcerative colitis. Gastroenterology 2019;156(6) Suppl1: OP1129Google Scholar
  15. 15.
    Ott SJ et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017; 152(4):799–811CrossRefGoogle Scholar
  16. 16.
    Phillips L et al. Marked Alterations in the viral genome in patients with recurrent Clostridium difficile infection before and after fecal microbiota transplant. Gastroenterology 2019;156(6) Suppl 1: OP426Google Scholar
  17. 17.
  18. 18.
    Cammarota G, Ianiro G, Tilg H et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–580CrossRefGoogle Scholar
  19. 19.
    Borren N et al. Impact of biologic therapy on resolution of fatigue symptoms in patients with active inflammatory bowel disease: a prospective cohort study. Gastroenterology 2019; 156(6): Sa1861Google Scholar
  20. 20.
    Borren N et al. Gut microbial dysbiosis contributes to fatigue in patients with quiescent inflammatory bowel diseases. Gastroenterology 2019; 156(6) Suppl 1: OP146.Google Scholar
  21. 21.
    Narula N et al. Risk of infectious complications from medical therapies in post-surgical patients. Gastroenterology 2019; 156(6) Suppl1: OP 640Google Scholar
  22. 22.
    Cohen BL et al. Anti-tumor necrosis factor therapy is not associated with postoperative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative infection (PUCCINI). Gastroenterology 2019; 156(6) Suppl1: OP 415aGoogle Scholar
  23. 23.
    Sands B et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833Google Scholar
  24. 24.
    Sands B et al. Efficacy in biologic failure and nonbiologic failure populations in a phase 3-study of ustekinumab in moderate-severe ulcerative colitis: UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833aGoogle Scholar
  25. 25.
    Sands B et al. Characterization of patients with delayed response to ustekinumab for Crohn’s disease. Gastroenterology 2019; 156(6) Suppl1: Tu 1725Google Scholar
  26. 26.
    Sands B et al. Vedolizumab shows superior efficacy versus adalimumab: results of VARSITY - the first head-to-head Study of biologic therapy for moderate to severe ulcerative colitis. Gastroenterology 2019; 156(6) Suppl1: LB Abstract 416aGoogle Scholar
  27. 27.
    Dubinky M et al. Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: data from the OCTAVE program. Gastroenterology 2019; 156(6) Suppl1: Sa 1872Google Scholar
  28. 28.
    Chiorean MV et al. Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. Gastroenterology 2019; 156(6) Suppl1: OP 798CrossRefGoogle Scholar
  29. 29.
    Hanes L et al. Gastroenterology 2019; 156(6) Suppl1: OP179Google Scholar
  30. 30.
  31. 31.
    Sugimoto K et al. Highly bioavailable curcumin (Theracurmin) for Crohn’s disease: randomized, multicenter, double-blind, placebo-controlled trial. Gastroenterology 2019; 156(6) Suppl1: Abstract Tu1716Google Scholar
  32. 32.
    Chandan S et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and metaanalysis of clinical trials. Gastroenterology 2019; 156(6) Suppl1: Abstrac Su1871CrossRefGoogle Scholar


  1. Digestive Disease Week (DDW) 18. – 21. Mai 2019 San Diego CA, USAGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.GFO Klinikum Bonn, St. Josef Hospital Bonn-BeuelBonnDeutschland
  2. 2.Internistisches Klinikum München SüdMünchenDeutschland

Personalised recommendations